CASI Pharmaceuticals reports net lack of $1.8 million for 1st quarter 2015 CASI Pharmaceuticals, Inc. , a biopharmaceutical firm focused on the acquisition, advancement and commercialization of innovative therapeutics addressing cancer tumor and various other unmet medical requirements for the global marketplace with a commercial concentrate on China today reported economic results for the 90 days ended March 31, 2015 cialis 10 mg . The Company reported a net reduction for the first quarter of 2015 of , or per share, weighed against a net loss of , or per share, for the same period this past year.
If the cells don’t divide, the tumor doesn’t grow.’ Researchers at the University of Chicago Medication conducted the assessments on individual prostate tumors grafted into mice. After six weeks of daily CAPE dosages just, the tumor volume growth rate decreased by fifty %. ‘There are some important factors,’ added Dr. Samadi, ‘First, this intensive research hasn’t yet been conducted with men. Second, CAPE doesn’t kill prostate malignancy cells and it only arrests their growth for the duration of the procedure.’ Related StoriesNew RNA check of blood platelets can be used to detect location of cancerNew antenna-like device makes breast cancer medical procedures easier for surgeonsViralytics enters into clinical trial collaboration contract with MSDSome reports date the use of honeybee hive propolis to as soon as 350B.C.